Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0931 • ACR Convergence 2021
Early Improvement in Disease Activity Indices Predicts Achievement of Long-term Clinical Remissions, ASDAS Inactive Disease and Low BASDAI with Normal CRP, During TNF-α-inhibitor Therapy in Patients with Ankylosing Spondylitis
Sang Jin Lee, Na Ri Kim and Eon Nam, Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea
Background/Purpose: As biologic agents including tumor necrosis factor (TNF)-α inhibitors (TNFi) have been proven to improve enormously clinical outcomes for patients with ankylosing spondylitis (AS),…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, José Correa-Fernández⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…
Abstract Number: 0562 • ACR Convergence 2021
Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Patompong Ungprasert¹, Thanat Chaikijurajai², Karn Wijarnpreecha³ and Paul Kroner³, ¹Cleveland Clinic, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH, ³Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
Abstract Number: 0905 • ACR Convergence 2021
Artificial Neural Network for the Recognition of Active Inflammatory Changes Compatible with Axial Spondyloarthritis on Magnetic Resonance Imaging of Sacroiliac Joints
Denis Poddubnyy¹, Janis Vahldiek², Lisa Adams², Torsten Diekhoff², Fabian Proft², Mikhail Protopopov², Judith Rademacher², Valeria Rios Rodriguez², Murat Torgutalp², Stefan Niehues² and Keno Bressem², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Active inflammatory changes in sacroiliac joints (SIJ) compatible with axial spondyloarthritis - axSpA (first of all, subchondral bone marrow edema – BME / osteitis)…
Abstract Number: 0933 • ACR Convergence 2021
Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?
Walter Maksymowych¹, Robert Inman², Louis Bessette³, Proton Rahman⁴, Emmanouil Rampakakis⁵, Odalis Asin-Milan⁶, Meagan Rachich⁶, Anne Marilise Marrache⁶ and Allen Lehman⁶, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²University Health Network, Toronto, ON, Canada, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada
Background/Purpose: A treat-to-target (T2T) strategy has been advocated for the management of axSpA although no consensus exists as to the most appropriate target or the…
Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Nelly Ziade¹, Joe Rassi², Bassel Elzorkany³, Clementina López Medina⁴, Sherif Gamal³, Sani Hlais⁵, Maxime Dougados⁶ and Xenofon Baraliakos⁷, ¹Rheumatology Department, Saint-Joseph Medical University and Hotel-Dieu de France Hospital, Beirut, Lebanon, ²Department of Orthopedic Surgery, Hotel-Dieu de France, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon, ³Cairo University, Cairo, Egypt, Cairo, Egypt, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Department of Family Medicine, American University of Beirut/ Saint-Joseph University, Beirut, Lebanon, ⁶Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…
Abstract Number: 0047 • ACR Convergence 2021
A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
Holly Rosenzweig¹, Emily Vance², Rouhin sen³, Liron Caplan⁴ and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Colorado University Anschutz Medical Campus, Denver, CO, ⁴Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA patients have irregular neutrophil responses, as…
Abstract Number: 0361 • ACR Convergence 2021
Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, David Gálvez-Ruiz⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Physical activity is an essential component in axial spondyloarthritis (axSpA) care, improving physical and mental wellbeing. This analysis aims to identify factors associated with…
Abstract Number: 0565 • ACR Convergence 2021
Increased Risk for Inflammatory Arthritis in Veterans with Depression or Anxiety
Brian Breviu¹, Shaobo Pei¹, Matthew Kirkpatrick², Bingjian Feng¹ and Jessica Walsh³, ¹Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT
Background/Purpose: Depression and anxiety are common in patients with inflammatory arthritis (IA), and have been reported as risk factors for various inflammatory diseases. The study…
Abstract Number: 0907 • ACR Convergence 2021
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Stan Kieskamp¹, Rick Wilbrink², Freke Wink³, Reinhard Bos⁴, Hendrika Bootsma¹, Suzanne Arends¹ and Anneke Spoorenberg¹, ¹University Medical Center Groningen, Groningen, Netherlands, ²University of Groningen, Leeuwarden, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: In two years, approximately 10% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) progresses to ankylosing spondylitis (AS). There are no data available of more…
Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Javier Marrugo¹, Maude Bonin¹, Gilles Boire¹, Louis Bessette² and Ariel Masetto¹, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…
Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Antoni Chan¹, Kathryn Rigler¹ and Liz van Rossen², ¹Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ²East Kent NHS Foundation Trust, Kent, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…
Abstract Number: 0048 • ACR Convergence 2021
A Novel Technology to Study the Role of Intestinal Biology in Spondyloarthritis Pathogenesis: Human Colonic Organoids and Epithelial Monolayers
Manuel Rodriguez¹, Alec Furst¹, James T. Rosenbaum² and Tejpal Gill¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a complex genetic disease with strong association to the human leukocyte antigen (HLA)-B27. Several observations including frequent, occult histologic evidence…
Abstract Number: 0363 • ACR Convergence 2021
Disease Course and Disease Burden in Patients with Axial Spondyloarthritis: Results from 5-year Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Fabiana Ganz⁵ and Robert Inman⁶, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Madrid, Spain, ⁵Abbvie Inc., North Chicago, IL, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: Patients (pts) with axial SpA (axSpA) can be classified into radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) based on the presence or absence of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.